NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03529110,"DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]",https://clinicaltrials.gov/study/NCT03529110,,ACTIVE_NOT_RECRUITING,"This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane.",YES,Breast Cancer,DRUG: Trastuzumab deruxtecan (T-DXd)|DRUG: Ado-trastuzumab emtansine (T-DM1),"Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane, Progression-free survival (PFS) by BICR was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions., Up to 33 months (data cut-off)","Overall Survival (OS) in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane, Overall survival (OS) was defined as the time from the date of first dose of study drug to the date of death due to any cause., Up to 33 months (data cut-off)|Percentage of Participants With Objective Response Rate (ORR) Based on BICR and Investigator Assessment in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane, The Objective Response Rate (ORR) was defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by BICR and investigator assessment based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR is reported., Up to 33 months (data cut-off)|Duration of Response (DoR) Based on BICR and Investigator Assessment in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane, Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR in participants with confirmed CR/PR based on BICR and investigator assessment is reported., Up to 33 months (data cut-off)|Progression-Free Survival (PFS) Based on Investigator Assessment in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane, Progression-free survival (PFS) by investigator assessment was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions., Up to 33 months (data cut-off)",,Daiichi Sankyo,"Daiichi Sankyo Co., Ltd.|AstraZeneca",ALL,"ADULT, OLDER_ADULT",PHASE3,524,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,DS8201-A-U302|2018-000222-61|183976|DESTINY-B03|CTR20190378,2018-08-09,2021-05-21,2025-06-01,2018-05-18,2022-04-29,2024-06-12,"UCLA Hematology Oncology, Los Angeles, California, 90095, United States|Sharp Memorial Hospital, San Diego, California, 92123, United States|University of California San Francisco, San Francisco, California, 94115, United States|Innovative Clinical Research Institute, Whittier, California, 90603, United States|Washington Cancer Institute, Washington, District of Columbia, 20010, United States|Florida Cancer Specialists-Broadway, Fort Myers, Florida, 33916, United States|Florida Cancer Specialists NORTH, Saint Petersburg, Florida, 33705, United States|Piedmont Cancer Institute, PC, Atlanta, Georgia, 30318, United States|Loyola University Health System, Maywood, Illinois, 60153, United States|Norton Cancer Institute, Louisville, Kentucky, 40207, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States|North Shore Hematology Oncology Associates, PC, East Setauket, New York, 11733, United States|University of Rochester, Rochester, New York, 14642, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, 27157, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, 45267, United States|Seidman Cancer Center, Cleveland, Ohio, 44106, United States|The Ohio State University, Columbus, Ohio, 43210, United States|Dayton Physicians, LLC, Kettering, Ohio, 45409, United States|Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, 15213, United States|Tennessee Oncology- St Thomas Location, Nashville, Tennessee, 37205, United States|Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, 37232, United States|UT Southwestern Medical Center, Dallas, Texas, 75390, United States|Houston Methodist Hospital / Houston Methodist Cancer Center, Houston, Texas, 77030, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Millennium Oncology, Houston, Texas, 77090, United States|The University of Texas Health Science Center at Tyler, Tyler, Texas, 75708, United States|MultiCare Health System Institute for Research and Innovation, Auburn, Washington, 98001, United States|The Tweed Hospital, Tweed Heads, New South Wales, 2485, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Box Hill Hospital, Box Hill, Victoria, 3128, Australia|Peninsula and South Eastern Haematology & Oncology Group, Frankston, Victoria, 3199, Australia|Peter MacCallum Cancer, Melbourne, Victoria, 3000, Australia|St John of God Subiaco Hospital, Subiaco, Western Australia, 6008, Australia|Institut Jules-Bordet, Bruxelles, 1000, Belgium|Universitair Ziekenhuis Brussel, Bruxelles, 1090, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, 2650, Belgium|AZ Sint-Lucas - Campus Sint-Lucas, Gent, 9000, Belgium|Universitaire Ziekenhuizen Leuven, Leuven, 3000, Belgium|CHU UCL Namur site de Sainte Elisabeth, Namur, 5000, Belgium|NOB - Nucleo de Oncologia da Bahia, Salvador, Bahia, 40170-110, Brazil|Hospital Nossa Senhora da Conceição, Porto Alegre, Rio Grande Do Sul, 91350-200, Brazil|Catarina Pesquisa Clinica, Itajaí, Santa Catarina, 88301-220, Brazil|CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia, Santo André, Sao Paulo, 09060-650, Brazil|ICESP - Instituto do Cancer do Estado de São Paulo Octavio Frias de Oliveira, São Paulo, Sao Paulo, 01246-000, Brazil|Clínica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda., São Paulo, Sao Paulo, 01317-001, Brazil|Instituto Americas, Rio De Janeiro, 22793-080, Brazil|A. C. Camargo Cancer Center, São Paulo, 01509-900, Brazil|Tom Baker Cancer Centre, Calgary, Alberta, T2N 4N2, Canada|Toronto Sunnybrook Hospital, Toronto, Ontario, M4N 3M5, Canada|St. Mary's Hospital, Montréal, Quebec, H3T 1M5, Canada|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, 100021, China|Beijing Hospital, Beijing, Beijing, 100730, China|Sun Yat-sen University, Cancer Center, Guangzhou, Guangdong, 510060, China|Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510120, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China|The First Hospital of Jilin University, Chang chun, Jilin, 130021, China|Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, 110042, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 200032, China|West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, 300060, China|Sir Run Run Shaw Hospital Xiasha Branch, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, 310000, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China|Centre Paul Strauss, Strasbourg Cedex, Bas Rhin, 67000, France|Hôpital Nord - CHU Marseille, Marseille Cedex 20, Bouches-du-Rhone, 13915, France|Centre François Baclesse, Caen Cedex 05, Calvados, 14076, France|Clinique Victor Hugo - Centre Jean Bernard, Le Mans, Cedex 02, Sarthe, 72015, France|CARIO - Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie, Plérin, Cotes d'Armor, 22190, France|Centre Georges François Leclerc, Dijon cedex, Côte-d'Or, 21079, France|CHRU Jean Minjoz, Besançon, Doubs, 25030, France|Institut Bergonié, Bordeaux cedex, Gironde, 33076, France|Centre René Huguenin, Saint-Cloud, Hauts De Seine, 92110, France|ICM Val d'Aurelle, Montpellier, Herault, 34298, France|CRLCC Eugene Marquis, Rennes cedex, Ille Et Vilaine, 35042, France|ICO - Site René Gauducheau, Saint-Herblain, Loire Atlantique, 44805, France|ICO - Site Paul Papin, Angers Cedex 2, Maine Et Loire, 49055, France|Centre de cancerologie les Dentellieres, Valenciennes, Nord, 59300, France|Centre Leon Berard, Lyon Cedex 08, Rhone, 69373, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, Rhone, 69495, France|Institut Sainte Catherine, Avignon Cedex 9, Vaculuse, 84918, France|Hôpital d'Instruction des Armees Begin, Saint-Mandé, Val De Marne, 94160, France|Institut Gustave Roussy, Villejuif cedex, Val De Marne, 94805, France|Institut Curie - site de Paris, Paris, 75005, France|Hôpital Saint-Louis, Paris, 75010, France|Hopital Tenon, Paris, 75020, France|Universitaetsklinikum Erlangen, Erlangen, Bayern, 91-54, Germany|Rotkreuzklinikum Muenchen gGmbH, Muenchen, Bayern, 80637, Germany|Klinikum rechts der Isar der TU Muenchen, Muenchen, Bayern, 81675, Germany|Universitaetsklinikum Duesseldorf AoeR, Düsseldorf, Nordrhein Westfalen, 40225, Germany|Haematologisch-Onkologische Schwerpunktpraxis, Troisdorf, Nordrhein Westfalen, 53840, Germany|Marienhospital Bottrop gGmbH, Bottrop, Rheinland Pfalz, 46236, Germany|Universitaetsklinikum Schleswig-Holstein - Campus Luebeck, Luebeck, Schleswig Holstein, 23538, Germany|The Chinese, Hong Kong, 00000, Hong Kong|The University of Hong Kong, Shatin, 00000, Hong Kong|Azienda Ospedaliera Universitaria Arcispedale Sant'Anna, Cona, Ferrara, 44124, Italy|Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo), U.O Oncologia Medica, Monza, Milano, 20900, Italy|Istituto Clinico Humanitas, Rozzano, Milano, 20089, Italy|IRCCS Centro di Riferimento Oncologico, Aviano, Pordenone, 33081, Italy|Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII), Bergamo, 24127, Italy|Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi, Bologna, 40138, Italy|Istituto Nazionale per la Ricerca sul Cancro di Genova, Genova, 16132, Italy|Azienda Ospealiera della Provincia di Lecco, Lecco, 23900, Italy|Azienda Ospedaliera Ospedali Riuniti Papardo-Piemonte, Messina, 98158, Italy|Ospedale San Raffaele, Milano, 20132, Italy|IEO Istituto Europeo di Oncologia, Milano, 20141, Italy|A.O.U. Policlinico di Modena, Modena, 41124, Italy|Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, 80131, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, 43100, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, 27100, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, 10126, Italy|Center Hospital of the National Center for Global Health and Medicine, Shinjuku-Ku, Tokyo-To, 162-8655, Japan|Aichi Cancer Center Hospital, Aichi, 464-8681, Japan|NHO Shikoku Cancer Center, Ehime, 791-0280, Japan|NHO Kyushu Cancer Center, Fukuoka, 811-1395, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima, 730-8518, Japan|NHO Hokkaido Cancer Center, Hokkaido, 003-0804, Japan|Kanagawa Cancer Center, Kanagawa, 241-8515, Japan|Kumamoto University Hospital, Kumamoto, 860-8556, Japan|Niigata Cancer Center, Niigata, 951-8566, Japan|Okayama University Hospital, Okayama, 700-8558, Japan|NHO Osaka National Hospital, Osaka, 540-0006, Japan|Osaka International Cancer Institute, Osaka, 541-8567, Japan|Saitama Cancer Center, Saitama, 362-0806, Japan|Shizuoka Cancer Center, Shizuoka, 411-8777, Japan|National Cancer Center Hospital, Tokyo, 104-0045, Japan|The Cancer Institute Hospital of JFCR, Tokyo, 135-8550, Japan|Showa University Hospital, Tokyo, 142-8666, Japan|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, 13620, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet De Llobregat, Barcelona, 08908, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, La Coruña, 15006, Spain|Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, La Coruña, 15706, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, 28222, Spain|Hospital Universitario Virgen Macarena, Sevilla, Sevill, 41009, Spain|Hospital Universitario de Canarias, San Cristobal de la Laguna, Tenerife, 38320, Spain|Hospital Infanta Cristina, Badajoz, 6007, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clinic de Barcelona, Barcelona, 08036, Spain|IOB-Institute of Oncology, Barcelona, 8023, Spain|Hospital General Universitario Gregorio Maranon, Madrid, 28007, Spain|MD Anderson Cancer Centre, Madrid, 28033, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Hospital Universitario Clinico San Carlos, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Clinico Universitario Virgen de la Victoria, Málaga, 29010, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain|China Medical University Hospital, Taichung, 40447, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan|National Taiwan University Hospital, Taipei, 100, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|Koo Foundation, Sun Yat-Sen Cancer Center, Taipei, 112, Taiwan|Royal Devon and Exeter Hospital (Wonford), Exeter, Devon, EX2 5DW, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, Grampian Region, AB25 2ZB, United Kingdom|Queen Mary University of London, London, Greater London, EC1M 6BQ, United Kingdom|University College London Hospitals, London, Greater London, NW1 2PG, United Kingdom|Guy's Hospital, London, Greater London, SE1 9RY, United Kingdom|Sarah Cannon Research Institute UK, London, Greater London, W1G 6AD, United Kingdom|The Christie Hospital, Manchester, Greater Manchester, M20 4BX, United Kingdom|Western General Hospital, Edinburgh, Lothian Region, EH4 2XU, United Kingdom|Nottingham University Hospitals City Campus, Nottingham, Nottinghamshire, NG5 1PB, United Kingdom|Royal Surrey County Hospital, Guildford, Surrey, GU2 7XX, United Kingdom","Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/10/NCT03529110/Prot_SAP_001.pdf"
